サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1641756

冠血流予備量比（FFR）の世界市場：製品別、技術別、用途別、エンドユーザー別 - 機会分析と産業予測（2024年～2035年）

Fractional Flow Reserve Market By Product, By Technology, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2024-2035

出版日
ページ情報
英文 350 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
冠血流予備量比（FFR）の世界市場：製品別、技術別、用途別、エンドユーザー別 - 機会分析と産業予測（2024年～2035年）
出版日: 2024年11月01日
発行: Allied Market Research
ページ情報: 英文 350 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の冠血流予備量比（FFR）の市場規模は、2023年に9億130万米ドルと評価され、2024年～2035年にCAGR9.1%で成長し、2035年には25億5,834万米ドルに達すると予測されています。 冠血流予備量比（FFR）は、冠動脈狭窄が血流に与える影響を評価することで、その重症度を評価するために使用される診断測定です。

FFRは、冠動脈の閉塞部のすぐ先で測定された圧力（遠位側圧力、Pd）と、閉塞部の手前、通常は大動脈または動脈の健康な部分で測定された圧力（近位側圧力、Pa）の比として定義されます。FFRの計算式はPd/Paです。

Fractional Flow Reserve Market-IMG1

FFRを評価する方法には侵襲的なものと非侵襲的なものがあります。侵襲的FFRには通常、冠動脈造影が含まれ、心臓カテーテル検査中に圧力センサーを備えたガイドワイヤーが冠動脈に挿入されます。このワイヤーは（しばしばアデノシンを用いて）誘導充血中に狭窄部の前後の圧力を測定します。これらの圧力の測定値はFFRの計算に使用されます。冠動脈内超音波検査（IVUS-FFR）は、動脈と狭窄の特徴を総合的に評価するために、画像診断と圧力測定を組み合わせたものです。非侵襲的な方法には血管造影FFRとコンピュータ断層撮影（CT）ベースのFFRがあります。X線血管造影FFRは血管を画像化し、血流動態を評価します。CTベースのFFRは、冠動脈の血流と圧力をシミュレートする高度な画像技術を採用しており、カテーテル治療を行うことなく狭窄の重症度を知ることができます。

FFRは冠動脈の狭窄がどの程度血流に影響を及ぼしているかを正確に評価し、狭窄が虚血（心筋の損傷につながる血流の減少）を引き起こす可能性があるかどうかを医師が判断するのに役立ちます。この検査では、アデノシンを投与して充血（血流が最大で血管抵抗が最小の状態）を誘導する必要があります。健康な動脈では、FFRは1に等しく、有意な閉塞がないことを示します。FFR値が0.8以下であれば重度の閉塞を示唆し、虚血の予測精度が高いです。FFRは冠動脈狭窄の生理学的影響に関する詳細な情報を提供することで、ステントやバイパス手術が必要かどうかなどの治療決定の指針となります。

心血管疾患、特に冠動脈疾患（CAD）の有病率の増加は、FFR市場成長の主要な促進要因です。冠動脈狭窄などの症状を患う患者が増えるにつれ、医療提供者は治療の意思決定、特に血管造影が必要かどうかを判断するための指針として、FFRを含む高度な診断ツールを求めています。例えば、英国心臓財団（British Heart Foundation）の報告書によると、2023年には世界で約1億1,000万人の男性と8,000万人の女性が冠動脈性心疾患を患っていると推定されています。これらの疾患は冠動脈の狭窄や閉塞を引き起こし、心筋への血流を減少させ、重症の場合は心臓発作を引き起こします。

さらに、CTから派生したAIベースのFFRのような技術的進歩の増加は、手術をより迅速でよりアクセスしやすくし、その採用を促進し、それによって市場の成長を促進します。例えば、デンバーを拠点とする医療テクノロジー企業Cleerly, Inc.は、医用画像診断結果に基づくAIを活用した冠動脈疾患（CAD）リスク評価を提供するCleerly ISCHEMIAソフトウェアデバイスを提供しています。さらに、有利な償還政策と最新の臨床ガイドラインの利用可能性は、ルーティンの心血管治療へのFFRの統合をサポートし、市場の成長を後押ししています。

しかし、特に小規模医療施設や医療予算が限られている地域にとっては、FFR装置の高価格が依然として大きな障壁となっており、市場の成長を抑制しています。加えて、FFR測定の実施と解釈には特殊な機器と訓練を受けた人材が必要であるため、特に発展途上の市場では導入が制限されています。一方、非侵襲的FFR技術の進歩は、診断手技をより低侵襲で身近なものにし、特に先進国や新興経済諸国において市場成長の機会を提供しています。さらに、新興市場における医療インフラの増加は、これらの地域で先進的な心血管診断ツールの導入が進むにつれて、大きな成長の可能性をもたらしています。

冠血流予備量比市場は、製品、技術、用途、エンドユーザー、地域に区分されます。製品別では、ガイドワイヤー、モニタリングシステム、アクセサリ・ソフトウェアに分類されます。技術別では、侵襲的モニタリングと非侵襲的モニタリングに分類されます。用途別では、市場は多枝CADと単枝CADに二分されます。エンドユーザー別では、市場は病院、心臓センター、その他に細分化されます。地域別では、市場は北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他欧州）、アジア太平洋（日本、中国、インド、オーストラリア、韓国、その他アジア太平洋）、ラテンアメリカ・中東・アフリカ（ブラジル、南アフリカ、サウジアラビア、その他）で調査されています。

利害関係者にとっての主なメリット

  • 当レポートでは、2023年～2035年の冠血流予備量比（FFR）分析の市場セグメント、現在の動向、推定、力学を定量的に分析し、優勢な冠血流予備量比（FFR）市場の機会を特定します。
  • 市場促進要因、市場抑制要因、市場機会に関連する情報とともに市場調査を提供します。
  • ポーターのファイブフォース分析では、利害関係者が利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるように、バイヤーとサプライヤーの潜在力を強調します。
  • 冠血流予備量比（FFR）市場のセグメンテーションの詳細な分析は、市場機会を決定するのに役立ちます。
  • 各地域の主要国は、世界市場への収益貢献度に応じてマッピングされています。
  • 市場企業のポジショニングはベンチマーキングを容易にし、市場企業の現在のポジションを明確に理解することができます。
  • 本レポートには、地域別および世界の冠血流予備量比（FFR）の市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析が含まれています。

本レポートで可能なレポートカスタマイズ（追加費用とタイムラインに関しましては販売担当へご連絡ください）

  • 国、地域、世界レベルでの患者/疫学データ
  • 規制ガイドライン
  • クライアントの関心に応じた追加企業プロファイル
  • 国別または地域別の追加分析：市場規模と予測
  • 企業プロファイルの拡張リスト
  • 過去の市場データ
  • SWOT分析

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 影響要因
    • 主な投資機会
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
      • 心血管疾患の有病率の上昇
      • 有利な償還政策
      • FFRに関するガイドラインの利用可能性
      • 低侵襲的・非侵襲的手術に対する需要の高まり
    • 抑制要因
      • FFR手術とデバイスの高コスト
    • 機会
      • 新興国における高い成長の可能性
      • FFRの進歩

第4章 冠血流予備量比（FFR）市場：製品別

  • 概要
  • ガイドワイヤー
  • モニタリングシステム
  • アクセサリー・ソフトウェア

第5章 冠血流予備量比（FFR）市場：技術別

  • 概要
  • 侵襲的モニタリング
  • 非侵襲的モニタリング

第6章 冠血流予備量比（FFR）市場：用途別

  • 概要
  • 単枝CAD
  • 多枝CAD

第7章 冠血流予備量比（FFR）市場：エンドユーザー別

  • 概要
  • 病院
  • 心臓センター
  • その他

第8章 冠血流予備量比（FFR）市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • その他
  • ラテンアメリカ・中東・アフリカ
    • ブラジル
    • 南アフリカ
    • サウジアラビア
    • その他

第9章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング：2023年

第10章 企業プロファイル

  • Haemonetics Corporation
  • Abbott Laboratories
  • Boston Scientific Corporation
  • Bracco
  • Koninklijke Philips N.V.
  • HeartFlow, Inc.
  • Esaote Group
  • CathWorks
  • Siemens
  • GE HealthCare
目次
Product Code: A10446

The global fractional flow reserve market was valued at $901.3 million in 2023, and is projected to reach $2,558.34 million by 2035, growing at a CAGR of 9.1% from 2024 to 2035.Fractional Flow Reserve (FFR) is a diagnostic measurement used to assess the severity of coronary artery stenosis (narrowing) by evaluating its impact on blood flow. FFR is defined as the ratio of the pressure measured in the coronary artery just beyond the blockage (distal pressure, Pd) to the pressure measured before the blockage, typically in the aorta or a healthy portion of the artery (proximal pressure, Pa). The formula for FFR is Pd/Pa.

Fractional Flow Reserve Market - IMG1

There are both invasive and non-invasive methods to assess FFR. Invasive FFR typically involves wired coronary angiography, where a pressure-sensor-equipped guide wire is inserted into the coronary artery during cardiac catheterization. This wire measures pressures before and after the stenosis during induced hyperemia (often using adenosine). These pressure readings are used to calculate the FFR. Intracoronary Ultrasound (IVUS-FFR), which combines imaging with pressure measurements to provide a comprehensive assessment of the artery and stenosis characteristics. Non-invasive methods include angiography-FFR and computed tomography (CT)-based FFR. X-ray Angiography-FFR uses imaging to visualize blood vessels and assess blood flow dynamics. CT-based FFR employs advanced imaging techniques to simulate blood flow and pressure in coronary arteries, providing insight into stenosis significance without catheterization.

FFR provides an accurate assessment of how much narrowing of coronary arteries is affecting blood flow, helping physicians determine whether the stenosis is likely to cause ischemia (reduced blood flow leading to heart muscle damage). The procedure requires the induction of hyperemia, a state of maximum blood flow and minimal vascular resistance, achieved by administering adenosine. In a healthy artery, FFR equals 1, indicating no significant obstruction. An FFR value of 0.8 or lower suggests a severe blockage, with high accuracy in predicting ischemia. FFR helps guide treatment decisions, including whether a stent or bypass surgery is needed by providing detailed information about the physiological impact of a coronary stenosis.

Increase in prevalence of cardiovascular diseases, particularly coronary artery diseases (CAD), is a major driver of FFR market growth. As more patients suffer from conditions such as coronary stenosis, healthcare providers seek advanced diagnostic tools including FFR to guide treatment decisions, specifically to determine whether angiography is necessary. For instance, as per the report of British Heart Foundation, in 2023, it was estimated that globally around 110 million men and 80 million women have coronary heart disease. These conditions result in the narrowing or blocking of coronary arteries, leading to reduced blood flow to the heart muscle and, in severe cases, heart attacks, which lead to surge in demand for fractional flow reserve procedure.

In addition, rise in technological advancements, such as AI-based FFR derived from CT, make the procedure faster and more accessible, encouraging its adoption, thereby fostering market growth. For instance, Cleerly, Inc., a Denver-based healthcare technology company provides Cleerly ISCHEMIA software device that delivers AI-powered coronary artery disease (CAD) risk assessments based on medical imaging results. Further, favorable reimbursement policies and the availability of updated clinical guidelines support FFR integration into routine cardiovascular care, boosting market growth.

However, high cost of FFR devices remains a significant barrier, particularly for smaller healthcare facilities or regions with limited healthcare budgets, thereby restricting market growth. In addition, the need for specialized equipment and trained personnel to perform and interpret FFR measurements limit adoption, especially in underdeveloped markets. On the other hand, advancements in non-invasive FFR technologies, which make diagnostic procedures less invasive and more accessible, provide an opportunity for market growth especially in the developed and emerging economies. In addition, the rise in healthcare infrastructure in emerging markets offers significant growth potential as these regions increasingly adopt advanced cardiovascular diagnostic tools.

The fractional flow reserve market is segmented into product, technology, application, end user, and region. On the basis of the product, it is classified into guidewires, monitoring systems, and accessories & software. On the basis of technology, the market is categorized into invasive monitoring and non-invasive monitoring. On the basis of application, the market is bifurcated into multi-vessel CAD and single-vessel CAD. On the basis of end user, the market is fragmented into hospitals, cardiac centres, and others. Region-wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, Rest of LAMEA).

The major companies profiled in the report include Haemonetics Corporation, Abbott Laboratories, Boston Scientific Corporation, Bracco, Koninklijke Philips N.V., HeartFlow, Inc., CathWorks, Siemens, GE HealthCare, and Esaote Group. The key players operating in the market have adopted product approval, acquisition, and agreement as their key strategies to expand their product portfolio. For instance, in December 2023, Haemonetics Corporation completed its previously announced acquisition of OpSens Inc., a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology. OpSens offers the OptoWire, a pressure guidewire that aims to improve clinical outcomes by accurately and consistently measuring Fractional Flow Reserve (FFR).

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the fractional flow reserve market analysis from 2023 to 2035 to identify the prevailing fractional flow reserve market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the fractional flow reserve market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global fractional flow reserve market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Application

  • Single vessel CAD
  • Multi vessel CAD

By Product

  • Guidewires
  • Monitoring Systems
  • Accessories and Software

By Technology

  • Invasive Monitoring
  • Non invasive Monitoring

By End User

  • Hospitals
  • Cardiac Centres
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • Abbott Laboratories
    • Boston Scientific Corporation
    • Bracco
    • CathWorks
    • Esaote Group
    • GE HealthCare
    • Haemonetics Corporation
    • HeartFlow, Inc.
    • Koninklijke Philips N.V.
    • Siemens

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rising prevalence of cardiovascular diseases
      • 3.4.1.2. Favorable reimbursement policies
      • 3.4.1.3. Availability of guidelines for FFR
      • 3.4.1.4. Growing demand for minimally invasive & non-invasive procedures
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of FFR procedures and devices
    • 3.4.3. Opportunities
      • 3.4.3.1. High growth potential in emerging countries
      • 3.4.3.2. Advancements in FFR

CHAPTER 4: FRACTIONAL FLOW RESERVE MARKET, BY PRODUCT

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Guidewires
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Monitoring Systems
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Accessories and Software
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: FRACTIONAL FLOW RESERVE MARKET, BY TECHNOLOGY

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Invasive Monitoring
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Non invasive Monitoring
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: FRACTIONAL FLOW RESERVE MARKET, BY APPLICATION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Single vessel CAD
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Multi vessel CAD
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country

CHAPTER 7: FRACTIONAL FLOW RESERVE MARKET, BY END USER

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Hospitals
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by region
    • 7.2.3. Market share analysis by country
  • 7.3. Cardiac Centres
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by region
    • 7.3.3. Market share analysis by country
  • 7.4. Others
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by region
    • 7.4.3. Market share analysis by country

CHAPTER 8: FRACTIONAL FLOW RESERVE MARKET, BY REGION

  • 8.1. Overview
    • 8.1.1. Market size and forecast By Region
  • 8.2. North America
    • 8.2.1. Key market trends, growth factors and opportunities
    • 8.2.2. Market size and forecast, by Product
    • 8.2.3. Market size and forecast, by Technology
    • 8.2.4. Market size and forecast, by Application
    • 8.2.5. Market size and forecast, by End User
    • 8.2.6. Market size and forecast, by country
      • 8.2.6.1. U.S.
      • 8.2.6.1.1. Market size and forecast, by Product
      • 8.2.6.1.2. Market size and forecast, by Technology
      • 8.2.6.1.3. Market size and forecast, by Application
      • 8.2.6.1.4. Market size and forecast, by End User
      • 8.2.6.2. Canada
      • 8.2.6.2.1. Market size and forecast, by Product
      • 8.2.6.2.2. Market size and forecast, by Technology
      • 8.2.6.2.3. Market size and forecast, by Application
      • 8.2.6.2.4. Market size and forecast, by End User
      • 8.2.6.3. Mexico
      • 8.2.6.3.1. Market size and forecast, by Product
      • 8.2.6.3.2. Market size and forecast, by Technology
      • 8.2.6.3.3. Market size and forecast, by Application
      • 8.2.6.3.4. Market size and forecast, by End User
  • 8.3. Europe
    • 8.3.1. Key market trends, growth factors and opportunities
    • 8.3.2. Market size and forecast, by Product
    • 8.3.3. Market size and forecast, by Technology
    • 8.3.4. Market size and forecast, by Application
    • 8.3.5. Market size and forecast, by End User
    • 8.3.6. Market size and forecast, by country
      • 8.3.6.1. Germany
      • 8.3.6.1.1. Market size and forecast, by Product
      • 8.3.6.1.2. Market size and forecast, by Technology
      • 8.3.6.1.3. Market size and forecast, by Application
      • 8.3.6.1.4. Market size and forecast, by End User
      • 8.3.6.2. France
      • 8.3.6.2.1. Market size and forecast, by Product
      • 8.3.6.2.2. Market size and forecast, by Technology
      • 8.3.6.2.3. Market size and forecast, by Application
      • 8.3.6.2.4. Market size and forecast, by End User
      • 8.3.6.3. UK
      • 8.3.6.3.1. Market size and forecast, by Product
      • 8.3.6.3.2. Market size and forecast, by Technology
      • 8.3.6.3.3. Market size and forecast, by Application
      • 8.3.6.3.4. Market size and forecast, by End User
      • 8.3.6.4. Italy
      • 8.3.6.4.1. Market size and forecast, by Product
      • 8.3.6.4.2. Market size and forecast, by Technology
      • 8.3.6.4.3. Market size and forecast, by Application
      • 8.3.6.4.4. Market size and forecast, by End User
      • 8.3.6.5. Spain
      • 8.3.6.5.1. Market size and forecast, by Product
      • 8.3.6.5.2. Market size and forecast, by Technology
      • 8.3.6.5.3. Market size and forecast, by Application
      • 8.3.6.5.4. Market size and forecast, by End User
      • 8.3.6.6. Rest of Europe
      • 8.3.6.6.1. Market size and forecast, by Product
      • 8.3.6.6.2. Market size and forecast, by Technology
      • 8.3.6.6.3. Market size and forecast, by Application
      • 8.3.6.6.4. Market size and forecast, by End User
  • 8.4. Asia-Pacific
    • 8.4.1. Key market trends, growth factors and opportunities
    • 8.4.2. Market size and forecast, by Product
    • 8.4.3. Market size and forecast, by Technology
    • 8.4.4. Market size and forecast, by Application
    • 8.4.5. Market size and forecast, by End User
    • 8.4.6. Market size and forecast, by country
      • 8.4.6.1. Japan
      • 8.4.6.1.1. Market size and forecast, by Product
      • 8.4.6.1.2. Market size and forecast, by Technology
      • 8.4.6.1.3. Market size and forecast, by Application
      • 8.4.6.1.4. Market size and forecast, by End User
      • 8.4.6.2. China
      • 8.4.6.2.1. Market size and forecast, by Product
      • 8.4.6.2.2. Market size and forecast, by Technology
      • 8.4.6.2.3. Market size and forecast, by Application
      • 8.4.6.2.4. Market size and forecast, by End User
      • 8.4.6.3. India
      • 8.4.6.3.1. Market size and forecast, by Product
      • 8.4.6.3.2. Market size and forecast, by Technology
      • 8.4.6.3.3. Market size and forecast, by Application
      • 8.4.6.3.4. Market size and forecast, by End User
      • 8.4.6.4. Australia
      • 8.4.6.4.1. Market size and forecast, by Product
      • 8.4.6.4.2. Market size and forecast, by Technology
      • 8.4.6.4.3. Market size and forecast, by Application
      • 8.4.6.4.4. Market size and forecast, by End User
      • 8.4.6.5. South Korea
      • 8.4.6.5.1. Market size and forecast, by Product
      • 8.4.6.5.2. Market size and forecast, by Technology
      • 8.4.6.5.3. Market size and forecast, by Application
      • 8.4.6.5.4. Market size and forecast, by End User
      • 8.4.6.6. Rest of Asia-Pacific
      • 8.4.6.6.1. Market size and forecast, by Product
      • 8.4.6.6.2. Market size and forecast, by Technology
      • 8.4.6.6.3. Market size and forecast, by Application
      • 8.4.6.6.4. Market size and forecast, by End User
  • 8.5. LAMEA
    • 8.5.1. Key market trends, growth factors and opportunities
    • 8.5.2. Market size and forecast, by Product
    • 8.5.3. Market size and forecast, by Technology
    • 8.5.4. Market size and forecast, by Application
    • 8.5.5. Market size and forecast, by End User
    • 8.5.6. Market size and forecast, by country
      • 8.5.6.1. Brazil
      • 8.5.6.1.1. Market size and forecast, by Product
      • 8.5.6.1.2. Market size and forecast, by Technology
      • 8.5.6.1.3. Market size and forecast, by Application
      • 8.5.6.1.4. Market size and forecast, by End User
      • 8.5.6.2. South Africa
      • 8.5.6.2.1. Market size and forecast, by Product
      • 8.5.6.2.2. Market size and forecast, by Technology
      • 8.5.6.2.3. Market size and forecast, by Application
      • 8.5.6.2.4. Market size and forecast, by End User
      • 8.5.6.3. Saudi Arabia
      • 8.5.6.3.1. Market size and forecast, by Product
      • 8.5.6.3.2. Market size and forecast, by Technology
      • 8.5.6.3.3. Market size and forecast, by Application
      • 8.5.6.3.4. Market size and forecast, by End User
      • 8.5.6.4. Rest of LAMEA
      • 8.5.6.4.1. Market size and forecast, by Product
      • 8.5.6.4.2. Market size and forecast, by Technology
      • 8.5.6.4.3. Market size and forecast, by Application
      • 8.5.6.4.4. Market size and forecast, by End User

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product mapping of top 10 player
  • 9.4. Competitive dashboard
  • 9.5. Competitive heatmap
  • 9.6. Top player positioning, 2023

CHAPTER 10: COMPANY PROFILES

  • 10.1. Haemonetics Corporation
    • 10.1.1. Company overview
    • 10.1.2. Key executives
    • 10.1.3. Company snapshot
    • 10.1.4. Operating business segments
    • 10.1.5. Product portfolio
    • 10.1.6. Business performance
    • 10.1.7. Key strategic moves and developments
  • 10.2. Abbott Laboratories
    • 10.2.1. Company overview
    • 10.2.2. Key executives
    • 10.2.3. Company snapshot
    • 10.2.4. Operating business segments
    • 10.2.5. Product portfolio
    • 10.2.6. Business performance
    • 10.2.7. Key strategic moves and developments
  • 10.3. Boston Scientific Corporation
    • 10.3.1. Company overview
    • 10.3.2. Key executives
    • 10.3.3. Company snapshot
    • 10.3.4. Operating business segments
    • 10.3.5. Product portfolio
    • 10.3.6. Business performance
  • 10.4. Bracco
    • 10.4.1. Company overview
    • 10.4.2. Key executives
    • 10.4.3. Company snapshot
    • 10.4.4. Operating business segments
    • 10.4.5. Product portfolio
  • 10.5. Koninklijke Philips N.V.
    • 10.5.1. Company overview
    • 10.5.2. Key executives
    • 10.5.3. Company snapshot
    • 10.5.4. Operating business segments
    • 10.5.5. Product portfolio
    • 10.5.6. Business performance
  • 10.6. HeartFlow, Inc.
    • 10.6.1. Company overview
    • 10.6.2. Key executives
    • 10.6.3. Company snapshot
    • 10.6.4. Operating business segments
    • 10.6.5. Product portfolio
  • 10.7. Esaote Group
    • 10.7.1. Company overview
    • 10.7.2. Key executives
    • 10.7.3. Company snapshot
    • 10.7.4. Operating business segments
    • 10.7.5. Product portfolio
  • 10.8. CathWorks
    • 10.8.1. Company overview
    • 10.8.2. Key executives
    • 10.8.3. Company snapshot
    • 10.8.4. Operating business segments
    • 10.8.5. Product portfolio
    • 10.8.6. Key strategic moves and developments
  • 10.9. Siemens
    • 10.9.1. Company overview
    • 10.9.2. Key executives
    • 10.9.3. Company snapshot
    • 10.9.4. Operating business segments
    • 10.9.5. Product portfolio
    • 10.9.6. Business performance
    • 10.9.7. Key strategic moves and developments
  • 10.10. GE HealthCare
    • 10.10.1. Company overview
    • 10.10.2. Key executives
    • 10.10.3. Company snapshot
    • 10.10.4. Operating business segments
    • 10.10.5. Product portfolio
    • 10.10.6. Business performance
    • 10.10.7. Key strategic moves and developments